Kornimate/medical-research-clean huggingface dataset:
prevention, access to rights, catch-up vaccination, treatment of conditions during pregnancy and for children

Conditions: HIV Infection

Summary: insufficient screening and diagnostic delay play a significant role in sustaining the hiv epidemic by france. gender inequalities major factors reinforce social inequalities in order to of heterosexual men born abroad the most later diagnosed with hiv infection. those gender differences are largely due to efficiency antenatal hiv screening, offered to women every pregnancy and widely accepted: a billed hiv serology in the context of pregnancy monitoring was found for 92% pregnant women benefiting from health insurance in 2015 the health of men is not taken into account in prenatal follow-up current french. the maternity hospital drains a population largely immigrant, often precarious the male prenatal consultation exists but it is not organized: it is possible to implement it, provided that the constraints exerted on men are taken into account. the projet study the feasibility and the implementation processes place of prenatal consultation of future fathers

insufficient screening and diagnostic delay play a significant role in sustaining the hiv epidemic by france. no significant decline is recorded in heterosexual, whether born in france or abroad. gender inequalities major factors reinforce social inequalities in order to of heterosexual men born abroad the most later diagnosed with hiv infection. those gender differences are largely due to efficiency antenatal hiv screening, offered to women every pregnancy and widely accepted: a billed hiv serology in the context of pregnancy monitoring was found for 92% pregnant women benefiting from health insurance in 2015. the arrival of a child could be an opportunity to screening for the future father as well. however, well that a consultation and a biological assessment intended for future fathers are provided for and fully reimbursed by the social security, the health of men is not taken into account in prenatal follow-up current french. the maternity hospital drains a population largely immigrant, often precarious. she puts in contact with the care of pregnant women who were sometimes distant, but not their companions: beyond the issue of reduction of the hidden hiv epidemic, increased needs for prevention and access to health appeared to us for the pilot phase of this project.

Eligibility criteria:
inclusion criteria: * for future fathers * are eligible for a prenatal consultation all adult men living in ile de france whose companion is followed at the intercommunal hospital of montreuil for a pregnancy evolutionary. * having expressed no opposition to participation in the research for future mothers * all adult women newly enrolled in the maternity ward of the montreuil intercommunal hospital centre for a progressive pregnancy declaring a partner involved in pregnancy and residing in ile de france. * having expressed no opposition to participation in the research exclusion criteria: * persons who are unable to give their non-opposition due to a poor understanding of the french language

Keywords: hiv prevention pregnancy health
efficacy and safety of intranasal ketorolac for the acute treatment of migraine

Conditions: Migraine

Summary: the study evaluates the efficacy and safety of using ketorolac as a nasal spray for the acute treatment of migraine.

evaluates the efficacy and safety of using ketorolac as a nasal spray for the acute treatment of migraine.

Eligibility criteria:
inclusion criteria: * diagnosis of migraine with or without aura (ihs criteria 1.1 and 1.2.1); * onset of migraine prior to age 50; * 2-8 moderate to severe migraine headaches per month exclusion criteria: * subjects receiving any investigational drug within 30 days before study entry; * more than 15 headache days per month; * known allergy or hypersensitivity to ketorolac and/or excipients; * allergy to aspirin or other nsaids; * currently receiving other nsaids or aspirin; * medical history that would preclude nsaid use

Keywords: migraine ketorolac
sleep and stent study: a multicentre, prospective study

Conditions: Obstructive Sleep Apnea

Summary: elucidating the effects of obstructive sleep apnea (osa) on cardiovascular outcomes is crucial in risk assessments and therapeutic recommendations for affected individuals. the sleep and stent study is a multi-center observational study investigating the relationships between osa and cardiovascular outcomes in patients treated with percutaneous coronary intervention (pci).

preliminary data suggest that osa may lead to adverse cardiovascular outcomes after pci. however, existing data were generated from small-scale, single-center studies. therefore, in the sleep and stent study, the investigators aim to conduct a large-scale multi-national cohort study to determine the association between osa and the incidence of adverse cardiovascular outcomes over a long-term follow-up period. the investigators hypothesize that osa is an independent risk factor for the development of major adverse cardiovascular and cerebrovascular events (macces) in coronary artery disease patients treated with pci. results from the sleep and stent study will advance the fundamental understanding of the burden and prognostic implications of osa in patients undergoing pci for coronary artery disease.

Eligibility criteria:
inclusion criteria: * age ≥18 years old and \< 80 years old * successful pci to at least one of the epicardial coronary arteries exclusion criteria: * known osa on cpap treatment * intubation for mechanical ventilation * intra-aortic balloon pump or other hemodynamic support device * sedation or other muscle relaxant given before overnight sleep study * perceived high risk of malignant ventricular arrhythmia * cardiogenic shock with systolic blood pressure \<90 mmhg * clinical heart failure requiring oxygen supplementation * pregnancy * history of malignancy (except non-melanoma skin cancer, cervical in-situ carcinoma, breast ductal carcinoma in situ or stage 1 prostate carcinoma)

Keywords: sleep apnea stent coronary artery disease percutaneous coronary intervention
effectiveness of peer-delivered trauma-specific treatment

Conditions: Post-Traumatic Stress Disorder; Substance Use Disorders

Summary: patient-centered trauma treatment, i.e., treatment delivered by peers with lived-experience, has the potential to increase access to trauma treatment in underserved communities. this could positively impact the lives of millions of people as 70% of adults in the u.s have experienced a traumatic event and the consequences of trauma are devastating and far reaching, including chronic and comorbid physical and mental health problems. the most known consequences of trauma include post-traumatic stress disorder (ptsd) and substance use disorders (suds). seeking safety (ss) is the most effective evidenced-based treatment for co-occurring trauma, ptsd and suds. while no specific degree or experience level is required to conduct ss, all the evidence comes from studies using trained clinicians to implement the treatment, including social workers, psychologists, and psychiatrists. however, these research findings do not generalize to underserved communities that lack mental health professionals. innovative approaches to treatment, such as peer-delivered services, are required to meet the demand for care in underserved areas. while the benefits of peer-delivered services have been well-documented in many areas, the value of peers in the provision of trauma-treatment is unknown. a theoretical basis supports the potential for peer-delivered trauma-treatment to be effective in addition to the strong therapist-patient bond, (i.e. therapeutic alliance (ta), which is an important predictor of treatment outcome and a typical result of peer-patient relationships. our research question is whether there is a difference between peer-led ss (pl-ss) groups and clinician-led ss (cl-ss) groups in improving the lives of people with trauma, ptsd and suds? the investigators have three specific aims: 1. determine the effectiveness of pl-ss groups compared to cl-ss groups in decreasing substance use and ptsd symptoms and improving coping skills, overall mental health and physical health. hypothesis: pl-ss compared to cl-ss groups will be as effective in improving outcomes. 2. compare levels of ta among pl-ss and cl-ss groups and examine the impact of ta on outcomes.hypotheses: levels of ta will be higher and will play more of a role in impacting outcomes in the pl-ss compared to cl-ss groups. 3. determine if the standard seeking safety instructor training (ss-it) is adequate for peers. hypothesis: peers will identify topics that will enhance the ss-it.


Eligibility criteria:
inclusion criteria: * be a member of inside out, a peer-run wellness center * be at least 18 years old * have a history of trauma * meet dsm-iv diagnostic criteria for lifetime and current full or sub-threshold ptsd * meet dsm-iv diagnostic criteria for current substance abuse or dependence * be able to provide informed consent to participate in the study. exclusion criteria: * live outside of catchment area * suicidal * pending immediate incarceration

Keywords: trauma post traumatic stress disorder substance use disorders peer-delivered trauma treatment
assessment of the anterior loop of the ian in a sample of egyptian population using cbct

Conditions: Mandibular Nerve

Summary: in this study the prevalence \& length of the anterior loop of the inferior alveolar nerve will be calculated and measured on retrospective cbct patient's scans

the proper knowledge of anatomical structures and their precise position is of a paramount importance for different dental specialties. the inferior alveolar nerve (ian) canal is one of the most important anatomical landmarks in the mandible shaban et al., 2017. by definition the inferior alveolar nerve (ian) is a terminal division of the mandibular branch of the trigeminal nerve, it is confined within the mandibular canal and innervates all the mandibular teeth. the ian initiates from the mandibular foramen and goes obliquely downward and forward in the ramus, and then horizontally within the body of the mandible. the ian gives off the mental nerve, which exits the mandible through the mental foramen, supplying sensory branches to the chin, lower lip, mucous membranes and the gingiva; from the midline to about the second premolar region. it then continues its path anteriorly and turn into the mandibular incisive nerve, which innervates the mandibular canines and incisors siddiqui et al. 2018. before leaving the mental foramen and branching into the incisive nerve, the ian may continue anteriorly and form an anterior loop (al). this anterior loop is the part where the ian directs mesially and occlusally before reversing direction and coursing distally towards the mental foramen ragu et al., 2019. during implant planning and other surgical procedures knowing the presence of the anterior loop and its length is very crucial to avoid its injury. specially concerning implantology where the location of the mental foramen and anterior loop determines the most distal point for implant placement in the interforaminal area; in order to avoid any injury resulting in sensory disturbances in this area panjnoush et al., 2016 recently, several studies have been published discussing the prevalence and length measurement of the anterior loop in many populations. however, no published researches were done on the egyptian population. therefore, this study is designed to assess the presence of the anterior loop and its length in a sample of egyptian population using cbct.

Eligibility criteria:
inclusion criteria: * cbct scans of adult egyptian patients, males and females. * cbct scans with unilateral or bilateral anterior mandibles; with minimum 2 mm length distal to the mental foramen exclusion criteria: * cbct images of poor quality or artifacts interfering with the assessment of the anterior loop of ian. * scans showing any pathosis in the interforaminal area (tumor or impaction).

Keywords: presence of the anterior loop of the mental nerve (branching from the inferior alveolar nerve) will be recorded & its length will be measured
genotyping of non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer; Gene Abnormality

Summary: the logical next step is to integrate molecular profiling into the care of all patients with nsclc.

nsclc is an area of oncology in which clinicians are beginning to use specific tumor-associated molecular aberrations to assign and/or prioritize targeted therapies for patients. at this early stage, multiple hurdles remain before molecular profiling becomes a routine part of thoracic oncology practice. in particular, to develop specific targeted therapies for patients whose tumors harbor rare mutations, it will be important to identify appropriate candidates, design the appropriate trials, and execute the trials with adequate numbers to achieve the necessary endpoints. implementation will facilitate realization of the promise of molecularly tailored therapy, which could lead to more effective treatments with fewer side effects.

Eligibility criteria:
inclusion criteria: 1. patients who have participated or will be participating a lung cancer clinical trial that use egfr-tki or chemotherapy as first line or second line treatment. 2. pathologic or cytological confirmation of non-small cell lung cancer (nsclc) with available tissue 3. patients must understand and provide written informed consent prior to initiation of any study-specific procedures 4. have a life expectancy 3 months. 5. have stage iv nsclc (ajcc, 7th edition) 6. no or one prior systemic therapy for advanced or metastatic nsclc 6.1.adjuvant chemotherapy: the adjuvant chemotherapy (e.g. vinorelbine / cisplatin) should be counted as one prior systemic therapy if the interval between the completion of adjuvant chemotherapy and the documentation of recurrence within 12 months. 6.2.maintenance therapy: the maintenance therapy (e.g. pemetrexed) following the first-line systemic chemotherapy which achieved complete response, partial response, or stable disease should not be counted as one prior systemic therapy if the maintenance drug was used in first-line combination therapy 7. ≥20 years 8. ecog performance status 0 - 2 9. if there is no available archived tissue, the subject must consent to undergo a biopsy or surgical procedure to obtain tissue within 1 month prior to study entry, which may or may not be part of the patient's routine care for their malignancy. exclusion criteria: 1. prior history of another malignancy (other than cured basal cell carcinoma of the skin or cured in-situ carcinoma of the cervix) within 5 years of study entry. 2. known hiv infection. 3. if subject has no archival tissue and refuse to do any biopsy or surgery for molecular testing
behavior and driving safety study ii

Conditions: Alcoholic Intoxication

Summary: the purpose of this study is to determine whether brief motivational interviews reduce problematic drinking behavior among individuals arrested for the first time for driving under the influence of alcohol (dui).

despite extensive legislative, law enforcement, and public awareness efforts, driving under the influence of alcohol (dui) remains a major cause of mortality and loss of years of productive life. a brief motivational interview (bi) is a non-confrontational, patient-centered discussion during which the individual's motivation and confidence to change health-related behaviors are explored. previous studies of bis in health care settings suggest that bis administered after hospitalization for alcohol-related injury reduce the likelihood of repeat injury hospitalization and arrest for dui. this study will evaluate whether brief motivational interviews reduce problematic drinking behavior among individuals arrested for the first time for driving under the influence of alcohol (dui).

Eligibility criteria:
inclusion criteria: * first arrest for driving under the influence of alcohol * arrest involved operation of a motor vehicle * at least 18 years of age * english-speaking exclusion criteria: * arrest involved injury to another person

Keywords: automobile driving driving under the influence interview, psychological brief intervention brief motivational interview
treatment of sexual dysfunction in hypogonadal men with epilepsy with testosterone and either anastrozole or placebo

Conditions: Seizure Disorder; Hypogonadism; Erectile Dysfunction

Summary: the purpose of this study is to determine if treatment using a medication (anastrozole/arimidex), which lowers estrogen levels in the blood is better than placebo, a tablet that does not contain any active medication, when combined with testosterone replacement to treat reproductive and sexual dysfunction in men with epilepsy. anastrozole, the medication that is currently under study, does not, at this time, have fda approval for use for this indication.

this is a three-month study where baseline information is collected at the first visit and then each patient is started on treatment with testosterone supplementation and either anastrozole or placebo. lab tests, seizure frequency, sexual function and mood will be monitored on a monthly basis.

Eligibility criteria:
inclusion criteria: * subject must be a male between the ages of 18 and 50 years. * subject must have localization-related epilepsy with complex partial and/or secondary generalized seizures. * subject will meet criteria for hypogonadism (abnormally low bioactive testosterone levels and abnormally low scores on questionnaires of reproductive and sexual function). * subject will have had a normal urogenital and rectal/prostate exam during the year prior to entry. * subject will have had documentation of therapeutic range serum aed levels, a normal cbc, and hepatic enzyme (alt,ast, alkaline phosphatase) levels that are less than twofold elevated during the 6 months prior to entry. exclusion criteria: * subject that has taken hormones, major tranquilizers or antidepressants in the three months prior to entry.

Keywords: seizure epilepsy testosterone hormone sexual dysfunction hypogonadism men
baclofen as a perioperative analgesic adjuvant

Conditions: Pain

Summary: the purpose of this study is to determine whether a single, oral dose of baclofen alters postoperative opioid requirements.

postoperative pain continues to be a significant clinical problem. use of perioperative adjuvants has improved postoperative pain control. the gaba-b receptor agonist, baclofen, is an appropriate drug to trial as such an analgesic adjuvant. therefore, the investigators will conduct a study designed to determine whether or not a single, oral dose of baclofen given to patients undergoing kidney stone surgery will reduce postoperative opioid requirements measured in the first 24 hours following surgery.

Eligibility criteria:
inclusion criteria: * adult patients (age \>= 19 y.o.) scheduled for kidney stone-related surgery exclusion criteria: (note - there were no patients requiring exclusion) * history of allergy to baclofen * any condition which might limit appropriate report and treatment of postoperative pain (e.g., non-english speaking; severe psychiatric disease) * active history of cancer * potential for difficult airway as judged by attending anesthesiologist due to concerns there could be muscle weakness from the drug with consequent respiratory depression
efficacy and safety of hsk16149 capsule in the treatment of moderate and severe central neuropathic pain in china

Conditions: Central Neuropathic Pain

Summary: to evaluate the efficacy and safety of hsk16149 capsule in the treatment of moderate to severe central neuropathic pain compared with placebo.


Eligibility criteria:
inclusion criteria: 1. voluntarily sign an informed consent form; 2. able to read and complete survey questionnaires; 3. male or female patients aged ≥ 18 years old; 4. the subject has a medical history and symptoms related to central neuropathic pain, including spinal cord related neuropathic pain (subject enrollment ≥ 50%), post-stroke central neuropathic pain, parkinson's disease pain, and multiple sclerosis pain, and must meet the following criteria: a) pain duration ≥ 3 months; b) characteristics that conform to neuropathic pain: dn4 scale score ≥ 4 points; 5. during screening visits, patients were assessed to have an average pain visual analogue scale (vas) score of ≥ 40 mm over the past 24 hours. exclusion criteria: 1. the presence of other painful diseases that may affect the evaluation of neuropathic pain; 2. patients with spinal cord injury or stroke whose condition is unstable and is expected to require surgical treatment; 3. there is a chronic systemic disease that the investigator has assessed may affect the participant's participation in the study； 4. meet any of the following laboratory test results: a) hematology: wbc\ 2.5 × uln; or tbil\> 1.5 × uln; c) egfr\ 2.0 × uln; 5. women who are pregnant, planning to become pregnant during the study period, or breastfeeding; women who do not wish to use reliable contraceptive methods (including condoms, spermicides, or iuds) for 28 days after signing up for the icf from the beginning to the last trial drug administration, or who plan to use progesterone contraceptives during this period; 6. mechanical operators engaged in high-altitude work, motor vehicle driving and other dangerous activities during the study period; 7. participated in any other clinical study within 30 days prior to screening; 8. the investigator determined that there were other conditions that were not suitable for study participation.